Administration of nanodrugs in proper menstrual stage for maximal drug retention in breast cancer

Medical Hypotheses

Volumn 71, Issue 1, 2008, Pages 141-147

  You, Shaojin ^a   Li, Wei ^a  

^a ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; VASCULOTROPIN;

AMENORRHEA; ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RETENTION; HAIR LOSS; HUMAN; MENSTRUAL CYCLE; MUCOSA INFLAMMATION; NAUSEA; NEPHROSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TASTE; TUMOR GROWTH; VOMITING; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAPILLARY PERMEABILITY; CHRONOTHERAPY; DRUG DELIVERY SYSTEMS; ESTRUS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MENSTRUAL CYCLE; MICE; MODELS, BIOLOGICAL; NANOSTRUCTURES;

EID: 43949105850     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.12.018     Document Type: Article

References (40)

1. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 (1986) 6387-6392
2. Sledge Jr. G.W., and Miller K.D. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 39 (2003) 1668-1675
3. Brasch R., Pham C., Shames D., Roberts T., van Dijke K., van Bruggen N., Mann J., Ostrowitzki S., and Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7 (1997) 68-74
4. Pham C.D., Roberts T.P., van Bruggen N., Melnyk O., Mann J., Ferrara N., Cohen R.L., and Brasch R.C. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16 (1998) 225-230
5. Zebrowski B.K., Yano S., Liu W., Shaheen R.M., Hicklin D.J., Putnam Jr. J.B., and Ellis L.M. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5 (1999) 3364-3368
6. Wood P.A., Bove K., You S., Chambers A., and Hrushesky W.J. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther 4 (2005) 1065-1075
7. Dabrosin C. Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis 8 (2005) 127-136
8. Hyder S.M. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocrinol Relat Cancer 13 (2006) 667-687
9. Dabrosin C. Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J Clin Endocrinol Metab 88 (2003) 2695-2698
10. Bogin L., and Degani H. Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 62 (2002) 1948-1951
11. Klauber-DeMore N. Tumor biology of breast cancer in young women. Breast Dis 23 (2005) 9-15
12. Aebi S., and Pagani O. Treatment of premenopausal women with early breast cancer: old challenges and new opportunities. Drugs 67 (2007) 1393-1401
13. Colleoni M., Rotmensz N., Robertson C., Orlando L., Viale G., Renne G., Luini A., Veronesi P., Intra M., Orecchia R., Catalano G., Galimberti V., Nole F., Martinelli G., and Goldhirsch A. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13 (2002) 273-279
14. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
15. Di-Cosimo S., Alimonti A., Ferretti G., Sperduti I., Carlini P., Papaldo P., et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 15 (2004) 1065-1071
16. Meyer J.S. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol 8 (1977) 67-81
17. Wood P.A., and Hrushesky W.J. Sex cycle modulates cancer growth. Breast Cancer Res Treat 91 (2005) 95-102
18. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet (1896) 104-107
19. Cooper L.S., Gillett C.E., Patel N.K., Barnes D.M., and Fentiman I.S. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor. Cancer 86 (1999) 2053-2058
20. Saad Z., Bramwell V., Duff J., Girotti M., Jory T., Heathcote G., et al. Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg 81 (1994) 217-220
21. Bove K., Lincoln D.W., Wood P.A., and Hrushesky W.J. Fertility cycle influence on surgical breast cancer cure. Breast Cancer Res Treat 75 (2002) 65-72
22. Hrushesky W.J., Gruber S.A., Sothern R.B., Hoffman R.A., Lakatua D., Carlson A., et al. Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst 80 (1988) 1232-1237
23. Klauber-DeMore N., Van Zee K.J., Linkov I., Borgen P.I., and Gerald W.L. Biological behavior of human breast cancer micrometastases. Clin Cancer Res 7 (2001) 2434-2439
24. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1 (1995) 149-153
25. Balsari A., Casalini P., Tagliabue E., Greco M., Pilotti S., Agresti R., et al. Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Pathol 155 (1999) 1543-1547
26. Banka C.L., Lund C.V., Nguyen M.T., Pakchoian A.J., Mueller B.M., and Eliceiri B.P. Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 66 (2006) 3667-3672
27. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
28. Wahl A.F., Donaldson K.L., Mixan B.J., Trail P.A., and Siegall C.B. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int J Cancer 93 (2001) 590-600
29. Sinha B.K., Katki A.G., Batist G., Cowan K.H., and Myers C.E. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 26 (1987) 3776-3781
30. Bachur N.R., Yu F., Johnson R., Hickey R., Wu Y., and Malkas L. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 41 (1992) 993-998
31. Crespi M.D., Ivanier S.E., Genovese J., and Baldi A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 136 (1986) 521-528
32. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8 Suppl. 2 (2003) 3-9
33. Hortobagyi G.N., Buzdar A.U., Marcus C.E., and Smith T.L. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr (1986) 105-109
34. Singla A.K., Garg A., and Aggarwal D. Paclitaxel and its formulations. Int J Pharm 235 (2002) 179-192
35. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 (2005) 161-171
36. Muggia F.M. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 54 Suppl. 4 (1997) 22-29
37. Dexter D.L., Kowalski H.M., Blazar B.A., Fligiel Z., Vogel R., and Heppner G.H. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38 (1978) 3174-3181
38. Yoneda T., Michigami T., Yi B., Williams P.J., Niewolna M., and Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88 (2000) 2979-2988
39. Li C.Y., Shan S., Huang Q., Braun R.D., Lanzen J., Hu K., et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2000) 143-147
40. Pidgeon G.P., Barr M.P., Harmey J.H., Foley D.A., and Bouchier-Hayes D.J. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85 (2001) 273-278